A Phase 3 interventional study of Bupropion in Smoking Cessation, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by University of Kansas Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing bupropion in Smoking Cessation — 4 open to participants now, 4 under way, 2 of them phase 3. Bupropion · Smoking Cessation.
Among the 48 studies testing bupropion in Smoking Cessation, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 14 in phase 3, and was the 43rd registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →4 of the 48 studies testing bupropion in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
By country, each count listing its studies:
Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 15 · Phase 4 17
First in 1998; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 162 across the 48 interventional studies. Of the 42 that completed or were terminated, 22 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 48 have an industry lead sponsor. The 10 most frequent:
University of Kansas Medical Center is the lead sponsor of 493 studies on the registry; 111 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
13 studies in Smoking Cessation by University of Kansas Medical Center: 3 open now, 3 under way, 1 of them phase 3. Of 10 finished, 5 (50%) have results posted.
Among the 13 studies in Smoking Cessation by University of Kansas Medical Center, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 3, and was the 9th registered.
University of Kansas Medical Center’s Smoking Cessation studies by the year they started, since 2009.
1 of the studies testing bupropion in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 48 studies testing bupropion in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among University of Kansas Medical Center’s 13 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
The primary objective of this study is to evaluate extended use of bupropion with the goal of enhancing abstinence in African American daily smokers, including the full spectrum of light, moderate, and heavy smokers. A two-arm, randomized design will be used to evaluate the efficacy of extended (6 months) bupropion treatment compared to standard (7 weeks) bupropion treatment. Baseline randomization stratified by gender and cpd (≤10, >10cpd) will assign participants (N=500) to receive extended treatment (EXT; 24 weeks of bupropion, n=250) or standard treatment (ST; 7 weeks of bupropion, n=250). All participants will receive culturally-relevant, individualized smoking cessation counseling, including support for medication adherence, and will be followed through Month 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
Drug: Bupropion
250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
Drug: Bupropion
150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
Verified abstinence at Month 6
Participants receiving extended bupropion treatment will have significantly higher Month 6 verified point-prevalence abstinence than participants receiving standard bupropion treatment.
Time frame: Month 6
Adherence to medication
We will evaluate the concordance of a biological sample of bupropion level, observable pill count, and 3-day recall as measurements of medication adherence.
Time frame: Week 4
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Jan 2027, 47 months after the start.
Of 32 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's planned 47 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupropion
University of Kansas Medical Center →